Seeking Alpha

Compugen (CGEN +3.1%) announces that it will "significantly" broaden its monoclonal antibody...

Compugen (CGEN +3.1%) announces that it will "significantly" broaden its monoclonal antibody program and will establish preclinical development capabilities in-house instead of using third parties. The firm will take on $8M in funding from Israel-based Baize Investments to help move along its research program.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|